Item 2.02 Results of Operations and Financial Condition.
On
Pursuant to the terms of the Settlement, ViiV grants Gilead a broad worldwide
license and covenant not to sue relating to any past, present or future
development or commercialization of bictegravir. In connection with the
Settlement, the Company will (1) make a one-time payment to ViiV of
The information in Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Any statements contained in this report except for
historical information may be deemed to be forward-looking statements. Without
limiting the generality of the foregoing, words such as "may," "will," "expect,"
"believe," "anticipate," "hope," "intend," "plan," "project," "could,"
"estimate," or "continue" are intended to identify such forward-looking
statements. These statements are based upon our current expectations and speak
only as of the date hereof. Our actual results may differ materially and
adversely from those expressed in any forward-looking statements as a result of
numerous factors and uncertainties, including the risks and uncertainties
described in our most recent Annual Report on Form 10-K, subsequent Quarterly
Reports on Form 10-Q and other documents filed with the
© Edgar Online, source